LumiraDx Investor Presentation Deck

3 Application TAM* POC Specifications Commercial Status* lumiraDx™ Significant Progress in Meeting Community Based Testing Needs lumiraDx CRP ww Antimicrobial stewardship $300M Fingerstick sample, results in 4 min Commercially Available lumiraDx D-Dimer Rule out of Venous Thromboembolism $700M Fingerstick sample, results in 6 min Commercially Available lumniraDx INR Coagulation monitoring $500M Fingerstick sample, results in 1 min Commercially Available lumiraDx NT-proBNP Heart Failure diagnosis $350M Fingerstick sample, results in 12 min CE Mark Expected H2 2022 Launch lumiraDx HbAlc Diabetes screening & monitoring $1.3B www Fingerstick sample, results in 7 min CE Mark Expected H2 2022 Launch * Global Total Addressable Market: We estimated for each test based on our current assumptions, including the (a) existing market sizes, (b) central lab market that could move to the POC, and (c) expansion of diagnostic testing. Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide

View entire presentation